264 59 10MB
English Pages [190] Year 2020
Updates in Surgery
Ferdinando Cafiero Franco De Cian Editors
Current Management of Melanoma
Updates in Surgery
The aim of this series is to provide informative updates on hot topics in the areas of breast, endocrine, and abdominal surgery, surgical oncology, and coloproctology, and on new surgical techniques such as robotic surgery, laparoscopy, and minimally invasive surgery. Readers will find detailed guidance on patient selection, performance of surgical procedures, and avoidance of complications. In addition, a range of other important aspects are covered, from the role of new imaging tools to the use of combined treatments and postoperative care. The topics addressed by volumes in the series Updates in Surgery have been selected for their broad significance in collaboration with the Italian Society of Surgery. Each volume will assist surgical residents and fellows and practicing surgeons in reaching appropriate treatment decisions and achieving optimal outcomes. The series will also be highly relevant for surgical researchers. More information about this series at http://www.springer.com/series/8147
Ferdinando Cafiero • Franco De Cian Editors
Current Management of Melanoma Foreword by Paolo De Paolis
Editors Ferdinando Cafiero Department of Surgery IRCCS Ospedale Policlinico San Martino Genoa Italy
Franco De Cian Department of Surgery IRCCS Ospedale Policlinico San Martino Genoa Italy
The publication and the distribution of this volume have been supported by the Italian Society of Surgery ISSN 2280-9848 ISSN 2281-0854 (electronic) Updates in Surgery ISBN 978-3-030-45346-6 ISBN 978-3-030-45347-3 (eBook) https://doi.org/10.1007/978-3-030-45347-3 © Springer Nature Switzerland AG 2021 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Revision and editing: R. M. Martorelli, Scienzaperta (Novate Milanese, Italy) This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Foreword
The incidence rates of melanoma continue to rise in Italy and in most European countries. Therefore, it is a pleasure for me to introduce this high-quality and very useful book edited by Ferdinando Cafiero and Franco De Cian, focusing on the state of the art of melanoma clinical practice. Ferdinando and Franco, top experts in the field, engaged coworkers whose experience and scientific excellence have produced a complete collection of the most advanced aspects related to the epidemiology, diagnosis, and treatment of melanoma. Particular attention is paid to the role of nuclear medicine in mapping sentinel lymph nodes and staging metastatic melanoma, and to the sentinel lymph node biopsy. In effect, surgery for melanoma has recently changed, and completion lymph node dissection is now reserved for a limited number of patients. Furthermore, the book discusses the histopathological examination and prognostic factors. All the strictly surgical aspects related to primary melanoma and radical dissections are also extensively addressed. The volume is exhaustive and up-to-date in every aspect, and it represents a point of reference for both the very experienced and less experienced surgeons who deal with this condition. On behalf of the Italian Society of Surgery, I would like to thank all the eminent authors who collaborated in producing this important monograph. Turin, Italy September, 2020
Paolo De Paolis President Italian Society of Surgery
v
Preface
Melanoma is a neoplasm whose incidence is steadily increasing, especially in the Western world. It is certainly true that we tend to see more thin melanomas than in previous years, thanks to prevention and education campaigns for the population, which has come to see “the sun as a friend.” The use of sunscreens and the avoidance of exposure during the warmer hours, especially for subjects with certain phenotypes, have led to a significant reduction of advanced forms of melanoma, with an increase of diagnoses in the early stages. As in all cancers, early diagnosis implies a better prognosis and less invasive and more effective treatments. Regarding this monograph, we aimed to illustrate the most innovative aspects of surgical and medical therapy for melanoma, taking into consideration the criticality of some treatments, which have seen their indications change dramatically within a few years. The volume starts with a short history of melanoma to make clear that the first reports of melanoma had already appeared 2000 years ago and that the problem of lymph node involvement and wide excision of the primary lesion had already arisen in the 1800s. With regard to epidemiology, prevention, and clinical diagnosis, we have emphasized the importance of dermoscopy and digitalization of images to be able to have comparisons over time. One chapter, edited by plastic surgeons, concerns the removal of the primary lesion, excision margins, and types of reconstruction in certain districts such as the face, in which the removal can be more limited without implying a higher risk of oncological relapse. The contribution of pathological anatomy, both morphological and immunohistochemical, is fundamental for the prognostic factors related to infiltration and other features of melanoma. As far as diagnostic imaging is concerned, it seemed fundamental to include the role of nuclear medicine both in detecting distant metastases with positron-emission tomography (PET) and in identifying the sentinel lymph node also with the new tracers now available. Since this textbook is mainly concerned with surgical technique, we wished to discuss in detail the technique of sentinel lymph node biopsy, the rationale for selective dissection as well as its implications. The surgical technique is discussed with
vii
viii
Preface
regard to axillary dissection, groin and iliac-obturator dissection, and neck dissection, which is perhaps the most demanding procedure. Aspects related to surgical complications have also been addressed, in particular early and late complications. The treatment of metastatic lymph nodes has changed radically in the last 3 years, with completion dissection becoming less and less frequent, to the benefit of medical therapies now recognized as less invasive and more effective. It was also felt appropriate to describe the treatment of metastatic lesions. The role of surgery for metastases is reserved for oligometastatic subjects or patients under medical treatment with solitary growing lesions. Additional surgical indications are represented by palliative treatment in urgent settings for bleeding, perforation, and occlusion, or just palliation in order to improve quality of life. As for medical treatment, it seemed essential that a monograph on melanoma should discuss neoadjuvant therapy. As with many other solid tumors, it is possible to give chemotherapy or, in this case, immunotherapy or target therapy, and then to perform a more conservative surgical procedure and continue medical therapy. Adjuvant medical therapy is also increasingly tailored. The last two chapters deal with the medical treatment of advanced forms with survival effects that were unimaginable until a few years ago. Finally, the local and systemic treatment of brain metastases, in particular the use of radiotherapy and gamma knife are discussed. At the end of this complex endeavor, we wish to thank first of all the authors who provided their contributions, often under pressure of time. A special thanks goes to Matteo Mascherini, who was the true soul of the project and the true glue that held the authors of this monograph together: he was always punctual and precise. Finally, a heartfelt thanks to all Springer’s staff and to our “Cerberus” Marco Martorelli. Good reading! Genoa, Italy Genoa, Italy September 2020
Ferdinando Cafiero Franco De Cian
Contents
1 The History of Melanoma: From Incas to the Third Millennium �������� 1 Ferdinando Cafiero, Matteo Mascherini, and Pietro Paolo Tavilla 2 Epidemiology, Prevention and Clinical Diagnosis of Melanoma���������� 7 Pietro Quaglino, Paolo Fava, Paolo Broganelli, Lorenza Burzi, Elena Marra, Simone Ribero, and Maria Teresa Fierro 3 Treatment of Primary Melanoma������������������������������������������������������������ 17 Ilaria Baldelli, Pier Luigi Santi, and Edoardo Raposio 4 Histopathological Examination: The Keystone of Treatment of Melanoma������������������������������������������������������������������������ 27 Marina Gualco 5 Molecular Assessment in Patients with Melanoma: When and Why?���������������������������������������������������������������������������������������� 39 Bruna Dalmasso, Irene Vanni, William Bruno, Virginia Andreotti, Lorenza Pastorino, Francesco Spagnolo, and Paola Ghiorzo 6 New Melanoma Staging: Prognostic Factors������������������������������������������ 47 Francesco Spagnolo, Andrea Boutros, Elena Croce, Enrica Tanda, Federica Cecchi, and Paola Queirolo 7 The Role of Nuclear Medicine in Mapping Sentinel Lymph Nodes and Staging Metastatic Melanoma���������������������������������� 55 Giuseppe Villa and Federico Schenone 8 Methodological and Technological Evolution of Sentinel Lymph Node Biopsy: An 8-Year Experience ������������������������������������������ 71 Marco Gipponi, Nicola Solari, and Ferdinando Cafiero 9 The Rationale of Sentinel Lymph Node Biopsy�������������������������������������� 85 Ferdinando Cafiero, Marco Gipponi, Nicola Solari, Matteo Mascherini, and Franco De Cian 10 Surgical Technique and Indications for Radical Dissection: Axilla������ 97 Carlo Riccardo Rossi and Saveria Tropea
ix
x
Contents
11 Surgical Technique and Indications of Radical Dissection: Groin�������� 107 Nicola Solari, Ferdinando Cafiero, and Matteo Mascherini 12 Surgical Technique and Indications for Radical Dissection: Head and Neck ������������������������������������������������������������������������������������������ 115 Carlo Riccardo Rossi and Saveria Tropea 13 Management and Prevention of Lymphatic Complications of Radical Dissections�������������������������������������������������������������������������������� 125 Francesco Boccardo and Sara Dessalvi 14 Local Treatments of Locoregional Disease in the Setting of Melanoma ���������������������������������������������������������������������������������������������� 135 Nicola Solari and Matteo Mascherini 15 Role of Surgery for Metastatic Melanoma���������������������������������������������� 147 Franco De Cian and Matteo Mascherini 16 Medical Treatment of Melanoma: Adjuvant and Neoadjuvant Therapies���������������������������������������������������������������������� 157 Francesco Spagnolo, Enrica Tanda, Andrea Boutros, Federica Cecchi, and Paola Queirolo 17 Systemic Treatment in Advanced Melanoma������������������������������������������ 167 Francesco Spagnolo, Andrea Boutros, Enrica Tanda, Federica Cecchi, and Paola Queirolo 18 The Management of Melanoma Brain Metastases �������������������������������� 175 Stefano Vagge and Francesco Lupidi
Contributors
Virginia Andreotti Genetics of Rare Cancers, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Ilaria Baldelli Plastic and Reconstructive Surgery Unit, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Francesco Boccardo Lymphatic Surgery and Microsurgery Unit, Department of Cardio-Thoracic, Vascular and Endovascular Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Andrea Boutros Medical Oncology Unit 2, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Paolo Broganelli Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy William Bruno Genetics of Rare Cancers, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Lorenza Burzi Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Ferdinando Cafiero Surgery Unit 1, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Federica Cecchi Medical Oncology Unit 2, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Elena Croce Medical Oncology Unit 2, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Bruna Dalmasso Genetics of Rare Cancers, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Franco De Cian Surgical Clinic Unit 1, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Sara Dessalvi Lymphatic Surgery and Microsurgery Unit, Department of CardioThoracic, Vascular and Endovascular Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy xi
xii
Contributors
Paolo Fava Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Maria Teresa Fierro Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Paola Ghiorzo Genetics of Rare Cancers, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Marco Gipponi Breast Unit, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Marina Gualco Department of Pathological Anatomy and Histology, Villa Scassi Hospital, Genoa, Italy Francesco Lupidi Neurosurgery Unit, Ospedali Galliera, Genoa, Italy Elena Marra Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Matteo Mascherini Surgical Clinic Unit 1, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Lorenza Pastorino Genetics of Rare Cancers, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Pietro Quaglino Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Paola Queirolo Division of Medical Oncology for Melanoma, Sarcoma and Rare Tumors, IEO-European Institute of Oncology IRCCS, Milan, Italy Edoardo Raposio Plastic and Reconstructive Surgery Unit, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Simone Ribero Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy Carlo Riccardo Rossi Department of Surgical Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy Pier Luigi Santi Plastic and Reconstructive Surgery Unit, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Federico Schenone Nuclear Medicine Unit, Department of Diagnostic Imaging and Radiation Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Nicola Solari Minimally Invasive Surgery Unit, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Francesco Spagnolo Medical Oncology Unit 2, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Contributors
xiii
Enrica Tanda Medical Oncology Unit 2, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Pietro Paolo Tavilla Plastic and Reconstructive Surgery at Dermatologic Clinic, Department of Specialist Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Saveria Tropea Department of Surgical Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy Stefano Vagge Oncological Radiotherapy Unit, Department of Diagnostic Imaging and Radiation Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Irene Vanni Genetics of Rare Cancers, Department of Oncology and Hematology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy Giuseppe Villa Nuclear Medicine Unit, Department of Diagnostic Imaging and Radiation Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
1
The History of Melanoma: From Incas to the Third Millennium Ferdinando Cafiero, Matteo Mascherini, and Pietro Paolo Tavilla
1.1
rom Ancient Times to the Beginning F of the Twentieth Century
• The first evidence of melanoma belongs to the diffuse melanotic metastases found in the skeletons of pre-Columbian mummies in Peru, radiocarbon dated to the fourth century BC [1]. • In 1787, John Hunter, working in London, successfully removed a recurrent melanoma from the jaw of a 35-year-old man. Hunter reported the tumor to be “soft and black” and labeled it as a “cancerous fungous excrescence” [2]. The preserved tumor was later diagnosed as a melanoma in 1968, and is still housed in the Hunterian Museum at Lincoln’s Inn Fields in London, UK [3]. • René Laennec, the inventor of the stethoscope, was the father of the term “mélanose”, from the ancient Greek μέλᾱς, μέλαινᾰ, μέλᾰν. During a lecture in Paris in 1804, he used this noun to describe lung metastases [4]. • The natural history of the disease was first described by William Norris in 1820. In his “Case of fungoid disease” he particularized a case of a patient affected by melanoma, from local recurrence to death for metastases. He wrote “When removed, it recurred rapidly in the scar; groin nodal metastases preceded the development of F. Cafiero (*) Surgery Unit 1, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy e-mail: [email protected] M. Mascherini Surgical Clinic Unit 1, Department of Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy e-mail: [email protected] P. P. Tavilla Plastic and Reconstructive Surgery at Dermatologic Clinic, Department of Specialist Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy e-mail: [email protected] © Springer Nature Switzerland AG 2021 F. Cafiero, F. De Cian (eds.), Current Management of Melanoma, Updates in Surgery, https://doi.org/10.1007/978-3-030-45347-3_1
1
2
• • • • •
•
•
•
F. Cafiero et al.
multiple subcutaneous lesions, a cough, and death” [5]. Norris continued to collect several cases of melanoma and, in his paper published in 1857, he proposed a “wide excision” to prevent local recurrence. He was also the first to notice the correlation between pale phototype or high number of nevi and incidence of melanoma [6]. In 1840, Samuel Cooper wrote “The first lines of the theory and practice of surgery” and observed that the advanced stages of melanomas were untreatable, stating “the only chance for benefit depends upon the early removal of the disease” [7]. In 1851, Fergusson performed the first groin radical dissection for lymph nodal metastases. The surgical intervention was published in The Lancet [8]. In 1853, Sir James Paget described the transition from the radial growth to the vertical growth phase [9], and he identified this process as the breaking point for the development of distant recurrence. Sir Jonathan Hutchinson made the first description of subungual melanoma (1857) and determined that “early amputation is demanded” to prevent a high risk of recurrence of disease. In the second half of nineteenth century, the interest in lymph node recurrence and surgery increased. Based on previous studies and publications, the first site of melanoma metastases seemed to be the locoregional nodal basin. The development of anesthesia helped in the surgical treatment, which could be more invasive than in the past. In 1892, Herbert Snow, a London surgeon, proposed that all melanoma should be treated by a wide local excision and anticipatory gland excision. Snow stated that “it is essential to remove, whenever possible, those lymph glands which first receive the infective protoplasm, and bar its entrance into the blood, before they have undergone increase in bulk” and that “palpable enlargement of these glands is unfortunately but a late symptom of deposit therein: by the time it occurs there is almost always implication of deeper organs or tissues” [10]. On the basis of this concept of anticipation of disease, in the twentieth century some trials tried to compare prophylactic or elective lymph node dissection (ELND) to observational follow-up. In 1907, William Handley strongly recommended that the wide excision should be of 2 in. (5 cm) laterally and should include 2 in. (5 cm) of subcutaneous layer, to prevent the dissemination of disease through the just discovered lymphatic vessels [11]. This led to a very aggressive approach to treating the primary tumor, which lasted for more than half a century. The trend was similar to breast cancer treatment, in which Halsted advocated radical mastectomy as the best way to prolong survival. For many years, a wide excision of more than 2 cm, regardless of local stage, with or without prophylactic lymph nodal dissection, was the gold standard for melanoma treatment.
1.2
Recent History
• The first isolated limb perfusions (ILP) were performed in the 50s by the North American surgeons Creech and Krementz, for palliation of in-transit disease as an alternative to amputation; after a difficult start due to toxicity of the drugs escaping into the systemic circulation, the surgical technique improved together with patient outcomes.
1 The History of Melanoma: From Incas to the Third Millennium
3
• In the 60s and 70s Wallace Clark and Alexander Breslow proposed a standard scale to assess the prognosis of melanoma based upon the histological examination. Clark based his scale on the level of invasion from epidermis, to dermis and subcutaneous tissue [12]. Breslow stratified melanoma patients considering the total vertical depth of the melanoma from the granular layer of the epidermis to the area of deepest penetration into the skin [13, 14]. In both classifications, the lower the level or depth of invasion, the better the prognosis. With regard to the Clark and Breslow levels, clinicians could select patients for prophylactic lymph node dissection. • According to the relation between local stage and prognosis, Handley’s very wide excision was thought to be excessive and several randomized, prospective trials were performed: –– WHO trial: 1 cm vs. 3 cm (Breslow